ライフサイエンスコーパス: dosage form

1 drugs in a children-friendly, flexible solid dosage form.

2 the area of this complex controlled release dosage form.

3 capsule content and design and the delivered dosage form.

4 nsions from microns to the size of the final dosage form.

5 s when developing an oral controlled release dosage form.

6 to the once-a-day injection of the solution dosage form.

7 felodipine at different locations within the dosage form.

8 considerable potential for patient-specific dosage forms.

9 dominates the mechanical properties of solid dosage forms.

10 riate formulation design of the conventional dosage forms.

11 ioxidant activity that is present in various dosage forms.

12 f phage cocktails in specific pharmaceutical dosage forms.

13 lternative to conventional immediate-release dosage forms.

14 ion in spiked human serum and pharmaceutical dosage forms.

15 re development of IVIVC for complex non-oral dosage forms.

16 m and expulsion of conventional soluble drug dosage forms.

17 rent manufacturers and formulated in various dosage forms.

18 readily amenable to the development of solid dosage forms.

19 justing for drug shortages, market size, and dosage forms.

20 ies may use DBP or DEP as excipients in oral dosage forms.

21 nous or NG route followed by the alternative dosage form after a 72-hr washout period.

22 t microparticles were also formulated in two dosage forms, an aqueous suspension and a dry tablet, to

23 , causing slowed dissolution of the marketed dosage form and compromising the oral bioavailability of

24 cts is important both for rational design of dosage forms and subsequent quality control during manuf

25 to satisfy regulatory requirements for nasal dosage forms and the polymer nanoparticles alone were fo

26 licability of the analysis to pharmaceutical dosage forms and urine sample were also investigated.

27 in its bulk powder, different pharmaceutical dosage forms, and biological fluids (plasma and urine) u

28 in its bulk powder, different pharmaceutical dosage forms, and biological fluids (plasma and urine).

29 cokinetic models were developed for both the dosage forms, and simulations were performed for differe

30 ms present which result in poor retention of dosage forms, and the potential for irritation and other

31 Conventional adult dosage forms are often not suitable for the paediatric a

32 predictive design of immediate-release solid dosage forms by tailoring microstructures, and could be

33 velopments are crucial to meet demands where dosage forms cannot be manufactured rapidly or when a pe

34 esholds for the maximum number of oral solid dosage forms children at different ages can take.

35 s for fast field screening of pharmaceutical dosage forms containing beta lactam antibiotics or combi

36 medicinal applications, mainly through oral dosage forms (decoctions and infusions).

37 wettability must be considered in practical dosage form design.

38 (API) and was analyzed in a tabulated solid dosage form, embedded within commonly used excipients.

39 The melt-processed polymeric cellular dosage forms enable predictive design of immediate-relea

40 drug-eluting fibers are emerging as a novel dosage form for multipurpose prevention against sexually

41 gnosis and monitoring, and gastric-retentive dosage forms for prolonged drug delivery-typically incor

42 rs and healthcare workers prefer oral liquid dosage forms for young children, and had similar thresho

43 rs ago, the instability of proteins in these dosage forms has prevented their clinical use.

44 Establishing an IVIVC for non-oral dosage forms has remained extremely challenging due to t

45 rt channels can be adopted in the designs of dosage forms, implants or stents to enhance the release

46 ehicles, and highlight the importance of the dosage form in microbicide effectiveness.

47 ions of IVIVC for extended release (ER) oral dosage forms in 1997, IVIVC has been one of the most imp

48 e provides an exciting opportunity to tailor dosage forms in a single-step with minimal excipients an

49 n phase behavior of multicomponent amorphous dosage forms, in particular those containing poorly wate

50 However, these dosage forms, in particular, are poorly retained and tra

51 Conventional immediate release dosage forms involve compressing the powder with a disin

52 inkjet printing to produce drug loaded solid dosage forms is demonstrated using a naturally derived F

53 e time of drug release, from as large as the dosage form itself to as small as the thickness of the c

54 with data being collected directly from the dosage form itself.

55 TDT 067 is a novel carrier-based dosage form (liquid spray) of 15 mg/ml of terbinafine in

56 rams are underway for a new modified release dosage form of tacrolimus (MR-4), a new analog of leflun

57 rincipal matrix ingredient in the injectable dosage form of the drug, Cremophor EL (polyethoxylated c

58 ay provide a generic format for once-a-month dosage forms of potent drugs.

59 printing to manufacture a multi-active solid dosage form or so called polypill.

60 4 errors, 12.1%), using the wrong drug name, dosage form, or abbreviation (total of 79 errors, 11.4%,

61 d nomenclature factors (incorrect drug name, dosage form, or abbreviation) (93 errors, 13.4%).

62 inistered drugs is a critical factor guiding dosage form selection in drug development.

63 he development of IVIVC for complex non-oral dosage forms (such as parenteral polymeric microspheres/

64 The present immediate-release solid dosage forms, such as the oral tablets and capsules, com

65 l formulation of the active molecules into a dosage form suitable for the physiological environment.

66 In this article, we introduce cellular dosage forms that can be readily prepared from polymeric

67 In contrast to oral dosage forms, there is currently no clear consensus on a

68 This is the first vaginal dosage form to provide sustained delivery of milligram q

69 This allows the cellular dosage forms to achieve drug release rates over an order

70 croscopy to produce chemical images of solid dosage forms, typically in troubleshooting roles.

71 n significant advances in controlled release dosage forms used for contraception.

72 ion have hampered full capitalization of the dosage forms vast benefits.

73 o 20.5), and more likely to have one or more dosage forms voluntarily discontinued by the manufacture

74 Release of antibiotic from PCL-PVP dosage forms was shown over 5 days and was slower compar

75 sodium (EC-MPS) and sirolimus (SRL) in oral dosage forms was well-preserved.

76 Using a novel hydrogel dosage form, we demonstrate that the use of sub-micron g

77 Swallowing oral solid dosage forms whole or crushing/dissolving them and mixin

78 ion in spiked human serum and pharmaceutical dosage forms with acceptable recovery values.